Open AccessPS1092 TANDEM AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF ADULT T‐CELL LYMPHOBLASTIC LYMPHOMA: A MULTIPLE CENTER PROSPECTIVE STUDY IN SOUTHWESTERN CHINA
Author(s) -
Liu Y.,
Li J.,
Rao J.,
Wen Q.,
Wang S.,
Lou S.,
Yang T.,
Li B.,
Gao L.,
Zhang C.,
Kong P.,
Gao L.,
Wang M.,
Zhu L.,
Xiang X.,
Zhou S.,
Liu X.,
Peng X.,
Chen X.,
Zhong J.,
Zhang X.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000562660.49131.3f
Subject(s) - rituximab , medicine , ifosfamide , cyclophosphamide , lymphoblastic lymphoma , lymphoma , hematopoietic stem cell transplantation , lenalidomide , germinal center , population , oncology , progression free survival , diffuse large b cell lymphoma , single center , transplantation , autologous stem cell transplantation , chemotherapy , immunology , b cell , multiple myeloma , cisplatin , antibody , t cell , immune system , environmental health
Background: T‐cell lymphoblastic lymphoma (T‐LBL) is a highly aggressive form of lymphoma with poor clinical outcomes and lack of a standard treatment regimen. Aims: This study evaluated the safety and efficacy of tandem autologous hematopoietic stem cell transplantation (auto‐HSCT) treatment for adult T‐LBL and assessed factors affecting survival. Methods: Newly‐diagnosed adult T‐LBL patients (n = 160) were divided into three groups: chemotherapy (no HSCT) group (68 patients), single auto‐HSCT group (46 patients), and tandem auto‐HSCT group (46 patients). The measurement of primary outcome was progression‐free survival (PFS). The intermediate outcomes were progression/relapse rate and overall survival (OS). Additionally, this study analyzed factors influencing toxicities related to tandem auto‐HSCT treatment and patient prognosis. Results: The 3‐year progression/relapse rate of the tandem auto‐HSCT group was significantly lower than that of the single auto‐HSCT group and chemotherapy group (19.6% vs 45.7% and 70.6%, p < 0.05). The 3‐year PFS rate and OS rate of the tandem auto‐HSCT group (68.3% and 72.5%, respectively) were significantly higher than those of the single auto‐HSCT group (41.5% and 55.4%, respectively, p < 0.05) and the chemotherapy group (23.3% and 43.3%, respectively, p < 0.05). In the tandem auto‐HSCT group, age and disease status after the first transplantation impacted the OS and PFS. Multivariate analysis identified disease status after the first transplantation as the only independent prognostic factor for outcome in T‐LBL treated with tandem‐HSCT. Summary/Conclusion: Tandem auto‐HSCT improves long‐term survival of adult T‐LBL patients compared to recipients of chemotherapy alone or chemotherapy plus single auto‐HSCT and disease status after the first transplantation is an independent prognostic indicator for these patients.